RestorGenex and Diffusion Pharmaceuticals Announce Merger Agreement
December 15, 2015 16:05 ET
|
RestorGenex
--Proposed Merger Would Create an Oncology-Focused Biotechnology Company ----Combined Company Expects to Initiate Phase III Clinical Trial in GBM for Orphan Drug-Designated TSC in 2016--BUFFALO GROVE,...
RestorGenex Reports Third Quarter 2015 Financial Results
November 12, 2015 16:15 ET
|
RestorGenex
BUFFALO GROVE, Ill., Nov. 12, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex to Present at Two Upcoming Growth Conferences
October 06, 2015 07:00 ET
|
RestorGenex
BUFFALO GROVE, Ill., Oct. 6, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
September 03, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill., Sept. 3, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Reports Financial Results
August 12, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill., Aug. 12, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
July 14, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill., July 14, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Announces Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
June 23, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill. and ROME, June 23, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
June 19, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill., June 19, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
June 18, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill., June 18, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex CEO Featured in Equities.com Interview
June 16, 2015 06:30 ET
|
RestorGenex
BUFFALO GROVE, Ill., June 16, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...